ALAMEDA, Calif., Sept. 5, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, today announced the initiation of a Phase II trial for AV650 (tolperisone HCl) in the treatment of spasticity associated with multiple sclerosis (MS). This Phase II spasticity trial will evaluate the safety, tolerability and efficacy of AV650 in MS patients at doses up to 900mg for one month followed by an open-label safety extension. The trial will be conducted in top MS centers in Germany and several other European countries.
